DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 07/27/2026 has been entered.
Status of the application
Receipt of applicant’s remarks and claim amendments filed on 07/27/2026 are acknowledged.
In light of claim amendments, previous Claim Objections and 112(d) rejection are withdrawn.
With regard to 103 rejection, to address applicants arguments, the rejection is modified and further clarified with additional support of evidence.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-6, 9-10 and 25-27 are rejected under 35 U.S.C. 103 as being unpatentable over Saccone (US 2009/0081186 A1) in light of He (Experimental and Therapeutic Medicine, 2016, 12, 3375-3380).
For claim 1:
Saccone teaches a method of treating pancreatitis in a subject a therapeutically effective amount of a Galanin antagonist and/or a Galanin receptor antagonist, wherein Galanin antagonist and Galanin receptor antagonist (GalR) is M40 [see abstract, 0092-0093 and 0113].
Applicants specification defined “fibrotic disorders” and provided ‘chronic pancreatitis’ and ‘liver fibrosis’ as examples [see 0072]. Dependent claims 22-23 defined liver disease is liver fibrosis. Accordingly, treating pancreatitis of Saccone reads applicants claimed method of treating a liver disease.
Further, Saccone teaches that their invention provides a method of preventing and/or treating pancreatitis in a subject by administering therapeutically effective amount of a Galanin antagonist and/or a Galanin receptor antagonist [see 0011].
Differences is that Saccone is silent on exemplifying M40 for treating liver diseases.
This difference can be cured by the following reasoning:
Saccone provided enough guidance on M40 and its utility. So, it is obvious to extrapolate teachings of Saccone to treat liver diseases by administering applicants elected M40, since liver disease is part of pancreatitis, according to applicants definition for “fibrotic disorders”, which includes liver fibrosis and pancreatitis.
He teaches that galanin inhibits hepatic stellate cells activation and suppresses the profibrogenic features of these cells, and these effects might be medicated by GalR2. Thus galanin is a potential endogenous factor in the inhibition of liver fibrosis.
A combination of prior art references is only proper if a person of ordinary skill in the art at the time of the invention, faced with the same problem, would have been motivated to combine their teachings with a reasonable expectation of success. See KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007). Here, the technical fields and problems addressed by the references are not distinct from that of the present claimed invention.
For claims 2-3:
Saccone teaches the subject in their method is human [see 0035].
For claims 4-6:
Various methods of diagnosis of liver fibrosis are well known in the art. For example, these diseases can be diagnosed through a combination of physical exam, blood tests, including liver function test etc.
Similarly, risk of developing liver fibrosis are also known. For example, drinking too much alcohol, obesity, diabetes or high cholesterol can cause fatty liver disease etc.
Based on the above symptoms, a person can be identified for treating liver diseases or liver fibrosis
The limitations in claims 4-6 are trivial and do not add any weight to the claimed subject matter.
For claim 9-10:
Saccone teaches that their effective amount is therapeutically effective amount [see 0011] and prophylactic [see 0074].
For claim 25:
Saccone teaches a pharmaceutical composition for the active ingredients for treating pancreatitis [see title, 0002, 0013 and 0026].
For claims 26-27:
Saccone teaches that suitable dose regimen of the antagonist to treat pancreatitis may be intravenously, subcutaneously, intramuscularly or oral etc. [see 0146, 0152].
Based on the above established facts from the cited prior art, it appears that all the claimed elements, i.e, applicants individual components and their utility, were known in the prior art, and one skilled person in the art could have combined the elements as claimed by known relationships, with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art.
The motivation to combine the art can arise from the expectation that the prior art elements will perform their expected functions to achieve their expected results when combined for their common known purpose. See MPEP 2144.07. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention by taking the advantage of the teaching of the above cited reference and to make the instantly claimed method with a reasonable expectation of success.
The strongest rationale for combining references is a recognition, expressly or impliedly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent, that some advantage or expected beneficial result would have been produced by their combination. In re Sernaker, 702 F.2d 989, 994-95, 217 USPQ 1, 5-6 (Fed. Cir. 1983).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUDHAKAR KATAKAM whose telephone number is (571)272-9929. The examiner can normally be reached 8:30 am to 5 pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
SUDHAKAR KATAKAM
Primary Examiner
Art Unit 1658
/SUDHAKAR KATAKAM/Primary Examiner, Art Unit 1658